DATA GRAPHICS | Data Byte
PRMT5 inhibitor pipeline at least 13 compounds deep
The molecule BMS is gaining through its Mirati acquisition is one of at least seven that have started clinical testing
October 13, 2023 1:29 AM UTC
Its acquisition of Mirati, announced Monday, makes BMS the latest large pharma to enter the PRMT5 race. The target, which has a synthetic lethal relationship with a mutation found in about 15% of cancers, offers a rare opportunity that is proving too good for some oncology companies to pass up: a precision approach that maps to a large, tumor-agnostic patient population.
On top of the $4.8 billion Bristol Myers Squibb Co. (NYSE:BMY) is spending to buy Mirati Therapeutics Inc. (NASDAQ:MRTX), the pharma has offered a further $1 billion in a contingent value right tied to regulatory submission of PRMT5 inhibitor MRTX1719 within seven years to treat non-small cell lung cancer. The molecule is slated to start Phase II testing next half...